NED Biosystems, Inc.

Founded to allow patients to achieve and sustain No Evidence of Disease NED Biosystems™ is a clinical-stage biotech company developing innovative treatments unlike most available today. We begin with a focus on patients and their families. NED seeks to dramatically improve patients' outcomes with therapies that lack the toxicity and side effects of today's treatments, allowing patients a high quality of life. NED has initiated a multi-pronged approach to treating cancer through NED-170, the patented investigational cancer product that affects four key processes that advance all late-stage cancer with an anticipated well-tolerated safety profile. The same four processes that drive cancer are integral to COVID-19. NED has rapidly deployed its translational multi-pronged approach to the development of a prophylactic and treatment for COVID-19. NED-260, an investigational product, is designed to be the first orally administered combination for prophylaxis and treatment against COVID-19.